Acute Treatment Of Migraine clinical trials

Explore recruiting acute treatment of migraine clinical trials.

Recruiting acute treatment of migraine studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Acute Treatment Of Migraine trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

Randomized, Double-Blind, Placebo-Controlled, Multiple-Attack Study with an Open-Label Extension to Evaluate the Efficacy, Safety, Tolerability, and the Consistency of Effect of Atogepant for the Acute Treatment of Migraine (ECLIPSE)

Spain, Germany, Poland, Czechia, Belgium, Slovakia +4 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

H8H-MC-LAHW: A Phase 3, 12-Month, Open-Label Study of Lasmiditan in Pediatric Patients with Migraine - PIONEER-PEDS2

France, Germany, Spain, Italy, Belgium, Netherlands +1 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

C4951004 - BHV3000-406: A Phase 4, Randomized, Double-blind Placebo Controlled, Efficacy and Tolerability Trial of Rimegepant for the Acute Treatment of Migraine in Adults Unsuitable for Triptan Use

Finland, Germany, Sweden, Austria, Belgium, France +4 more

Therapeutic use (Phase IV) EU CTIS Study details

A Randomized, Parallel-Group, Single-Attack, Open-Label Study to Evaluate the Efficacy of Diclofenac Potassium and Rimegepant for the Acute Treatment of Migraine (ATOM).

Denmark

Therapeutic use (Phase IV) EU CTIS Study details

C4951002 Phase 3, multicenter, randomized, double-blind, group sequential, placebo-controlled study to assess efficacy and safety of rimegepant for the treatment of migraine (with or without aura) in children and adolescents ≥ 6 to < 18 years of age

Sweden, Poland, Spain

Therapeutic confirmatory (Phase III) EU CTIS Study details

H8H-MC-LAHV: Pediatric Options for Migraine Relief: A Randomized, Double-Blind, Placebo-Controlled Study of Lasmiditan for Acute Treatment of Migraine: PIONEER-PEDS1

Netherlands, Germany, Spain, Belgium, Romania, Italy +1 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

Acute Treatment Of Migraine trials by city

Acute Treatment Of Migraine in Toronto Acute Treatment Of Migraine in Vancouver Acute Treatment Of Migraine in Montreal Acute Treatment Of Migraine in Calgary Acute Treatment Of Migraine in Edmonton Acute Treatment Of Migraine in Ottawa Acute Treatment Of Migraine in Winnipeg Acute Treatment Of Migraine in Quebec City Acute Treatment Of Migraine in Hamilton Acute Treatment Of Migraine in Kitchener Acute Treatment Of Migraine in London Acute Treatment Of Migraine in Halifax Acute Treatment Of Migraine in New York Acute Treatment Of Migraine in Los Angeles Acute Treatment Of Migraine in Chicago Acute Treatment Of Migraine in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease